Interviewer. A senior clinical and mood disorder research psychiatrist.
Patients. Consecutive 320 bipolar-II (BP-II) and 243 major depressive disorder (MDD) outpatients, presenting voluntarily for MDE treatment. Substance-related and borderline personality disorders were excluded because of confounding diagnosis of BP-II, and rare in the setting. Clinically significant general medical illnesses and cognitive disorders were also excluded.
Interview methods. During the assessment visit (off psychoactive drugs for at least 2 weeks, apart from a few cases on small doses of benzodiazepines), the following instruments were used: (1) Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV) (First et al, 1997) . (2) Global Assessment of Functioning scale (GAF, in SCID-CV) for index MDE severity. (3) Family History Screen (Weissman et al, 2000) . Often, family members/close friends supplemented clinical information during interview. DSM-IV criteria for MDE with atypical features specifier (AD) were followed. 'Early onset' was defined as the onset of first MDE before age 21 years (according to Stewart et al, 2002) , 'chronic' as index MDE symptoms lasting more than 2 years. Variables often reported to distinguish atypical vs nonatypical depression were assessed (see references by Benazzi, Agosti and Stewart, 2001; Angst et al, 2002; Matza et al, 2003 and Rabkin et al, 1996) . Early-onset chronic AD (EO-C-AD) was compared to nonearly-onset, nonchronic AD (non-EO-C-AD).
Statistics
Logistic regression was used to study associations and to control for confounding and interactions (STATA 7). Pvalues were two-tailed, a level 0.05.
RESULTS
AD was present in 44.5% (251/563). EO-C-AD was present in 26.2% of AD (66/251). In the AD sample, univariate logistic regression of EO-C-AD vs BP-II, index age, female gender, recurrences, axis I comorbidity, GAF, bipolar family history, DSM-IV atypical symptoms, found significantly associated BP-II (odds ratio ¼ 2.2, 95% CI ¼ 1.2-4.0), age (odds ratio ¼ 0.9, 95% CI ¼ 0.9-0.9), more recurrences (odds ratio ¼ 4.4, 95% CI ¼ 2.3-8.3), more axis I comorbidity (odds ratio ¼ 2.4, 95% CI ¼ 1.4-4.4), more bipolar (I+II) family history (odds ratio ¼ 2.9, 95% CI ¼ 1.4-5.9), and hypersomnia (odds ratio ¼ 1.8, 95% CI ¼ 1.0-3.2). Multivariate logistic regression of EO-C-AD vs variables found significant in the univariate analysis (not including age), including all possible interactions, found that recurrences (odds ratio ¼ 4.3, 95% CI ¼ 1.8-10.0), axis I comorbidity (odds ratio ¼ 2.4, 95% CI ¼ 1.2-5.1), bipolar family history (odds ratio ¼ 2.7, 95% CI ¼ 1.2-6.1), and hypersomnia
DISCUSSION
Findings support, on clinical and family history grounds, a distinction between EO-C-AD and non-EO-C-AD. The findings support the pharmacological distinction found by Stewart et al (2002) .
